BioSpace News Archive

NANO-X IMAGING LTD today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024.

Nodexus Inc. today announced that William (Bill) Rhodes has been named Executive Chairman of the company’s Board of Directors.

Polaris AR , a developer of advanced mixed-reality surgical guidance technology, announced the first total knee arthroplasty (TKA) using its STELLAR Knee mixed-reality surgical guidance system.

Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.

Applied DNA Sciences, Inc. and Alphazyme LLC (Alphazyme), a Maravai LifeSciences company (MRVI) and global provider of specialty enzymes used in the life sciences sector, have entered into an agreement under which Alphazyme will scale-up manufacturing of Applied DNA’s proprietary Linea™ RNA polymerase (“RNAP”).

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update.

Co-Diagnostics, Inc. announced that Co-Dx CEO Dwight Egan will deliver the keynote address at the 5th Annual Infectious Disease Diagnostics and Molecular Diagnostics Conference, organized by MarketsandMarkets and held March 21-22, 2024, in London, England.

Brenig Therapeutics presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17, 2024.

Award Recognizes Exceptional Contributions by Women in the Life Sciences Industry

MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted novel therapeutics to improve the lives of patients suffering from debilitating CNS disorders, announced the appointment of Vishwas Setia as Chief Financial Officer.